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Abstract 
Background: Primary immunodeficiency (PID) is a heterogeneous group of inheritable genetic disorders with 
increased susceptibility to infections, autoimmunity, uncontrolled inflammation and malignancy. Timely precise 
diagnosis of these patients is very essential since they may not be able to live with their congenital immunity defects; 
otherwise, they could survive with appropriate treatment. DNA biobanks of such patients could be used for molecu-
lar and genetic testing, facilitating the detection of underlying mutations in known genes as well as the discovery of 
novel genes and pathways.
Methods: According to the last update of the International Union of Immunological Societies (IUIS) classification, 
patients are registered in our biobank during a period of 15 years. All patients’ data were collected via questionnaire 
and their blood samples were taken in order to extract and protect their DNA content.
Results: Our study comprised 197 patients diagnosed with PID. Antibody deficiency in 50 patients (25.4%), phago-
cytic defect in 47 patients (23.8%) and combined immunodeficiency with associated/syndromic feature in 19 patients 
(9.6%) were the most common PID diagnoses, respectively. The most common variant of PID in our study is common 
variable immunodeficiency, which accounted for 20 cases (10.1%), followed by chronic mucocutaneous candidiasis 
in 15 patients (7.9%) and congenital neutropenia in 13 patients (7%). Mean age at onset of disease was 4 years and 
mean age of diagnosis was 9.6 years. The average diagnostic delay was 5.5 years, with a range of 6 months to 46 years. 
Parental consanguinity and history of PID in family were observed in 70.2 and 48.9% of the patients, respectively. The 
majority of PID patients (93.3%) were from families with low socioeconomic status.
Conclusion: This prospective study was designed to establish a PID Biobank in order to have a high quality DNA res-
ervoir of these patients, shareable for international diagnostic and therapeutic collaborations. This article emphasizes 
the need to raise the awareness of society and general practitioners to achieve timely diagnosis of these patients and 
prevent current mismanagements.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Primary immunodeficiency (PID) refers to a complex 
genetic group of disorders characterized by defects in 
the immune system, resulting in high susceptibility to 
various infections [1]. Publications on PID patients have 
improved our knowledge that at present about 250 genes 
are involved in distinct immunodeficiency disorders [2]. 
A report from the Iranian Primary Immunodeficiency 
Registry (IPIDR) established the incidence of PID at 13 
per 1,000,000 population, and a mortality rate of 18.7%, 
approximately similar to the global mortality rate. 
Although significant advances in the identification of 
PIDs have been made, its prevalence is underestimated 
owing to lack of awareness of the public and general 
practitioners [3, 4].
Since most PIDs are inherited in an autosomal reces-
sive pattern, consanguineous marriage leads to a higher 
rate of their prevalence [5, 6]. Frequency of inter-family 
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marriage in Muslim societies such as Iran is higher than 
in non-Muslim societies [7–9]. Data from the IPIDR 
revealed that 63% of the PID patients have consanguine-
ous parents [4].
Biobanks are designed to store the samples and 
data from patients willing to participate in biomedical 
research. It also provides accessibility to patients’ sam-
ples for long-term evaluations, appropriate diagnosis 
and treatment [10]. It enables setting up links between 
medical centers around the world for research and thera-
peutic purposes, which would be particularly helpful for 
rare diseases [11]. In this study, we introduce a Biobank 
for PID patients (PIDB) with the aim of collecting and 
preserving sensitive data and biological samples. PIDB 
permits the assessment of the proportion of the affected 
individuals by genome sequencing and determining 
undiagnosed types of PID.
Necessity of creating a biobank
Inadequate sample availability and poor biospecimen 
quality are the limitations of the case–control and cohort 
studies, particularly in the field of genetic disorders [12, 
13]. Without a data and specimen bank, lots of time and 
material are wasted in each cross-sectional study. These 
limitations could be overcome by establishing a compre-
hensive biobank and database for affected patients. Stor-
age of blood samples accelerates the process of laboratory 
investigations and offers the opportunity of studying sev-
eral specimens simultaneously. Human DNA, a stable 
molecule containing genetic information, is extensively 
used for research purposes. The benefit of setting up a 
DNA bank is to overcome diagnostic limitations in our 
country by expansion of international collaborations. The 
collected samples could be distributed across borders for 




Our PID biobank is constructed under the support of 
our Immuno-Deficiency Research Center (IDRC) and 
managed by the head of this research center. Isfahan 
Immunodeficiency Association is a private charity asso-
ciation, which financially supports this project. It will be 
explained further that samples are primarily prepared in 
our center and are sent to the partner centers across the 
world. The Academic research collaboration agreements 
have been designed to carry out the genetic studies with-
out charge.
PIDB database
This retrospective study comprised patients with 
the diagnosis of PID who are referred to the clinical 
immunology clinics in Isfahan or are hospitalized in 
Alzahra hospital for receiving IVIg and other parental 
therapies. We used the criteria of European Society for 
Immunodeficiencies (ESID) and the International Union 
of Immunological Societies (IUIS-2014) for diagnosis 
of PID, from 2000 to 2015 [15, 16]. The family members 
of the patients who are suspected of any kind of PID or 
even presenting atypical manifestations are included in 
our survey. In particular, the individuals born to con-
sanguineous parents took priority in being investigated. 
All individuals were provided with an information sheet 
in which the purposes of creating the PIDB and possible 
further research were written. Each patient who agreed 
to participate in the project was given a unique code, 
which served as the label for the specimen tube and the 
data sheet. Data were collected through questionnaires 
including detailed demographic information, socioeco-
nomic status, parental consanguinity, family history of 
PID, number of deaths due to PID, first clinical manifes-
tations of disease, history of having recurrent infections, 
history of autoimmune disease, history of atopy, labora-
tory results, treatments, information from stored medical 
documents and interviews with patients. Data were col-
lected in Excel database and converted for analysis by the 
SPSS statistical software package version 16. The average 
maximum and minimum values were used for quantita-
tive variables. ANOVA was utilized to compare quantita-
tive variables for more than 2 groups. Pearson’s chi2 test 
was used to compare nominal/ordinal variables among 
groups. A p value lower than 0.05 was considered statisti-
cally significant.
PIDB sampling
After the inform consent had been signed, a 10-ml blood 
sample of each patient was taken in a tube with antico-
agulant for the extraction of DNA and RNA. The process 
of extraction was carried out with calibrated instruments 
according to standard protocols. It has been shown that 
adding citrate as anticoagulant yields higher quality 
RNA and DNA; however, Ethylene diamine tetra-acetic 
acid (EDTA)-coated collection tubes are also suitable 
for extraction of DNA and protein but may show some 
unwanted side effects [17]. Peripheral blood mononu-
clear cells (PBMC) were isolated from the buffy coat by 
Ficoll-Hypaque density gradient. All specimens were pro-
cessed and archived immediately after sample collection 
to avoid potential degradation, because a time difference 
between sampling and cryopreservation of the biomol-
ecules of more than 24 h could affect the quality of sam-
ples. Freshly obtained PBMC were processed for DNA 
and RNA extraction with the High Pure PCR template 
preparation Kit, and the cDNA that was synthesized with 
reverse transcriptase enzyme, were all kept at −70 °C. It 
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has been established that DNA is stable at 4 °C for weeks, 
at −20 °C for months and at −70 °C for years, so −70 °C 
is a suitable temperature for long-term stable storage of 
DNA. However, there is some evidences that RNA may 
be damaged over 5 years of maintenance at this tempera-
ture. All steps of sample preparation were performed by 
a trained team of nurses and technicians. The quality of 
samples in biobanks should be guaranteed, thus the used 
protocol provided rigorous quality assurance and control. 
We used spectrophotometry for rapid evaluation of the 
yield and purity of the extracted DNA and RNA. An OD 
260/280 ratio higher than 1.8 was considered an indicator 
of acceptably pure DNA/RNA, relatively free of protein. 
Since spectrophotometry does not reflect the integrity 
of the genomic content, agarose gel electrophoresis was 
applied as well. Concentration and yield was determined 
by comparing the sample DNA intensity to that of a DNA 
quantitation standard. To ensure that anonymity was 
preserved, specimens including DNA, RNA and cDNA 
were labeled with their identification codes.
PIDB role in medical research
Creation of a PIDB not only provides an opportunity to 
secure genetic information for further molecular stud-
ies but also describes epidemiological data on different 
types of PID [18]. This biorepository plays a significant 
role in the recognition of known gene mutations or new 
gene mutation discoveries by proper storing and process-
ing of the collected samples. A PIDB is a resource of large 
amounts of DNA, which is especially beneficial in genetic 




Informed consent is one of the major principles of eth-
ics that should be considered in DNA biobank studies 
as well as other research surveys in which specimens 
are obtained through intervention [19]. Consent allows 
patients to decide whether they are interested in partici-
pating in a study with a given sample of their body. All 
individuals have to be well informed about the purpose of 
the study and the associated risks and benefits, and then 
a voluntary consent with preserved rights of patients will 
be obtained. All participants are allowed to withdraw the 
consent at any time in the study. Since biobank samples 
are not prepared just for one study, consent from the 
donors has to be obtained for all further research except 
if the patients have agreed to continue with the usage of 
their samples under a broad consent form initially. We 
preferred to seek informed consent for one study; how-
ever, this requires re-contact of patients for any new 
purpose that has not been declared in the primary form. 
Frequent contact with the donor assures patients that the 
process of diagnosing their disease is continuing and has 
not been stopped because there has not been any notice-
able achievement. Since a dead participant cannot be re-
contacted, we agreed with the authors that if obtaining 
re-consent is impossible, it would be acceptable to re-use 
the samples without consent [20–22].
Most biobank studies do not contain samples of chil-
dren, because they do not always understand the purpose 
of research studies, they are not easily accessible, obtain-
ing samples from children requires more skills and also 
because they suffer relatively more than adults. Some 
authors believe that sharing data on children should not 
be allowed ethically until they reach adulthood and have 
the right to decide whether they want to be involved in 
the investigation [23]. However, other authors argue 
that the data will expire and the individual himself/her-
self cannot take the advantage [24]. In our study, which 
mainly comprised children, parents are the only eligi-
ble ones who could sign the informed consent on their 
behalf. This investigation was approved by the Medical 
Ethics Committee of the Isfahan University of Medical 
Sciences under approval no. 290130.
Participants’ privacy
One of the participants’ concerns in blood donation is 
confidentiality about their personal information [25]. 
Biobanks contain genetic information about each indi-
vidual with a specific phenotype. By using anonymous 
samples, the link between the lab and personal data is 
broken and just longitudinal epidemiologic results can 
be achieved. Best solution is coding data, which guaran-
tees the protection and is acceptable in standard research 
experiments [26–28].
We established clear policies to secure patients’ pri-
vacy, such as identifying different levels of access to the 
data by the employees of PIDB and encoding of biospeci-
mens and data [29].
There are some issues on the exchange of data and 
sharing of databases in international collaborations. In 
this situation, the risk of confidentiality breach increases, 
and this is the reason why most researchers are reluctant 
to have the data sets shared [30]. Our international col-
laboration is extremely encouraged, even by the patients, 
as it is not only reaching research goals but also gives aid 
in diagnosis of their disease. Hence, we took measures 
to maximize the patients’ privacy by transmitting coded 
data.
In this type of research, in which genetic biobank of a 
population of rare diseases is targeted, patients have to 
be notified on the concrete genetic findings relevant to 
their medical therapies once the final results have been 
prepared. The duty of informing patients equally and 
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immediately after their definite diagnosis is an obligatory 
principle.
Partnership
Identification of the genetic basis of a primary immuno-
deficiency disease requires sufficient number of cases and 
availability of high technologies to discover the molecu-
lar origin of genetic disorders. Following the establish-
ment of a PID biobank, a memorandum of understanding 
was signed between the Isfahan University of Medical 
Sciences and the Hanover Medical School and Ludwigs 
Maximillians University of Munich, Germany. Academic 
partnerships with France and Sweden for research and 
clinical collaborations were developed afterwards. As 
stated in the method section, DNA, RNA and cDNA 
samples from patients were prepared in accordance to the 
type of information to be obtained and the level of sensi-
tivity necessary. One of the techniques for gene expres-
sion profiles—RNA sequencing, exome sequencing and 
next generation sequencing—were applied. RNA tran-
scriptome sequencing mostly focused on gene expression 
profile and also detects alternative splicing events but 
apart from being costly and time consuming, its usage 
would be limited in genes with relatively low expression. 
In exome sequencing, because DNA is targeted, there is 
no difficulty in detecting low-expressed genes.
Results
The biobank of PID consists of 197 samples, 121 male and 
76 female, from 2000 to 2015. The classification of reg-
istered patient according to IUIS is presented in Table 1. 
Antibody deficiency and phagocytosis defects, includ-
ing number and/or function, were the most common 
groups of PID disease, with 50 patients and 47 patients, 
respectively. Other subcategories of PID were as follows: 
combined immunodeficiency with associated/syndro-
mic feature 19 cases, innate immunity disorders and auto 
inflammatory diseases each 13 cases, combined immu-
nodeficiency 12 cases, immune dysregulation 7 cases and 
complement deficiency 3 cases. 34 patients are presented 
with different manifestations of primary immunodefi-
ciency diseases but are not yet categorized in a specific 
group. CVID1 was the most common disorder, with 20 
patients. CGD2 (n =  14), CMC3 (n =  13), and MSMD4 
(n =  12) were also common PIDs defined in our regis-
tered patients.
Our survey resulted in a molecular genetic diagnosis 
for 33 out of 197 patients. Another 160 patients who were 
suspected of having PIDs according to clinical symptoms 
did not yet receive a genetic diagnosis. No mutation was 
detected in 4 cases by using targeted gene panel—which 
focuses on a set of relevant candidate genes with known 
diagnostic yield. Thus, the samples are under further 
investigations by applying whole exome sequencing 
(WES). Detailed genetic diagnosis of patients, includ-
ing the affected gene, the mutation, the PID subclass, the 
molecular genetic test by which the diagnosis was carried 
out and confirmation by Sanger sequencing are listed in 
Table  2. Most of the patients presented typical clinical 
manifestations of known PIDs, so that they were likely to 
be diagnosed based on a classical approach. Identifying 
gene mutations in the Iranian PID population resulted in 
2 novel mutation discoveries, JAGN15 and STK46 defi-
ciencies, which are the causes of a type of CVID and CID, 
respectively [31, 32].
Data analysis
Our data analysis revealed that the median age of the 
registered patient is 15 years and 10 months, with a wide 
range from 2 to 58 years. Median age at the onset of dis-
ease in different types of PID is 2.5 years, ranging from 
infancy to 58  years. We observed first signs and symp-
toms of PID in 34.8% of patients under 1  year and 50% 
under 2.5 years. Only 12 cases showed first clinical mani-
festations of PID after the age of 10 years. It is shown that 
median age of onset among patients with different types 
of PID has a minimum of 1 and a maximum of 5.5 years, 
which is attributed to phagocytic defect and complement 
deficiency, respectively.
The median age of diagnosis was 7 years, with a range 
of 7 months to 51 years. Phagocytic defects in number/
function accounts for the lowest mean age of diagnosis, 
which is 4  years, while innate immunity defect is diag-
nosed at older age, with a median age of 14  years and 
7  months. Diagnostic delay varied from 6  months to 
46  years, with a median of 3  years. The median period 
of 4.5 years of diagnosis delay was the highest in patients 
with auto inflammatory disease, and 2 years was the low-
est diagnostic delay seen in antibody deficiency patients. 
20.3% of patients (cases) were diagnosed a year after 
the onset of disease and diagnosis was made later than 
4 years after onset in about 38% of patients.
Ethnicity and religion were assessed in all patients. 
Almost all patients were Muslims, and 97% of patients 
were Persian. Two patients were Arab, 1 Turkish and 1 
Kurdish.
CID7, combined immunodeficiency with associated/
syndromic feature and antibody deficiency was observed 
threefold more frequently in males (M: F; 62:19). How-
ever, other PIDs affected males and females equally.
Among the different types of PID, parental consan-
guinity did not differ statistically. 100 and 22 patients 
had consanguineous parents, and 63.9% were children 
of first-cousin marriages. Highest rate of consanguinity 
was seen in combined immunodeficiency with associ-
ated/syndromic feature and CID7. History of PID in the 
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Table 2 Detailed genetic analysis of some PID patients from PIDB in Iran
ID Validated 
by Sanger
Method Disease Gene affected Mutation Comment
P1 No NGS Not known CDX1 (exone 3) G > A, p. E209D Heterozygous gene mutation in CDX1 
(exone 3)
P2 Yes NGS Ab def NFKB2 Not reported yet Frame shift mutation in NFKB2
P3 No CVID panel, WES UI* – – No deleterious mutation diagnosed in 
the CVID chip
P4 No Hyper IgE panel, WES UI* – – No promising data have been 
detected
P5 Yes NGS, Bruton BTK c.1783T > C, p.Y551H Missense mutation in BTK
P6 No CVID panel, WES UI* – – No deleterious mutation diagnosed in 
the CVID chip
P7 Yes NGS, Netherton syn-
drome
SPINK5 c.A/−, p.N755Mfs*27 Homozygous nonsense mutation in 
SPINK5; (Netherton)
P8(A) Yes Primary Ab def panel Bruton BTK c.115T > C, p.Y39H
P9(A) Yes Primary Ab def panel Bruton BTK c.115T > C, p.Y39H
P10 Yes NGS CID PIK3CD c.3061G > A,p.E1021 K Heterozygous mutation in the PIK3CD 
gene
P11 Yes NGS CID (MHC II def ) RFXANK c.438 + 5G > A RFXANK/BLS (Bare Lymphocyte 
Syndrome)
P12 Yes WES Phagocytic 
defect
STAT 1 c.1945C > T, p.R649C Heterozygous gene mutation in 
STAT 1
P13 No MSMD panel, WES UI* – – No mutation in MSMD genes
P14 No WES AT ATM gene (exon 
39)
c.5623C > T,p.Arg1875 Rare homozygous variants here; 
mutation in exon 39 of ATM gene in 
homozygous form ATM gene
P15 No NGS SCID PTPRC(CD45RO) c.2539A > G CD45RO deficiency
P16 (B) Yes WES CGD NCF1 Completely absent Complete lack of the NCF1 gene that 
encodes p47-phox, a component of 
NADPH oxidase enzyme. Only NCF1 
pseudogenes were found
P17 (B) Yes WES CGD NCF1 Completely absent Complete lack of the NCF1 gene that 
encodes p47-phox, a component of 
NADPH oxidase enzyme. Only NCF1 
pseudogenes were found
P18 Yes NGS WAS WAS non-reported Non-reported mutation in exon 8 was 
found as hemizygous (WAS)
P19 YES WES CID (CD40 def ) TNFRSF13B IVS3 + 25 A > C Heterozygote mutation in TNFRSF13B)
P20 (C) Yes WES LAD ITGB2 1670 G > C Mutation in ITGB2 gene (LAD I)
P21 (C) Yes WES LAD ITGB2 1670 G > C Mutation in ITGB2 gene (LAD I)
P22 Yes WES CGD (X-linked) CYBB (exon 3) c.252 + 5 G > C Mutation in exon 3 of CYBB gene on 
Ch-X
P23 (D) Yes WES FMF MEFV c.2282G > A:p.R761H/
c.2040G < C:p.
M680H
Homozygous mutation in MEFV gene
P24 (D) Yes WES FMF MEFV c.2040G < C:p.M680H Heterozygous mutation in MEFV gene
P25 (D) Yes WES FMF MEFV c.2282G > A:p.R761H Heterozygous mutation in MEFV gene
P26 (D) Yes WES FMF MEFV c.2282G > A:p.R761H Heterozygous mutation in MEFV gene
P27 (D) Yes WES FMF MEFV c.2040G < C:p.M680H Heterozygous mutation in MEFV gene
P28 Yes WES SCN JAGN1 c.59G > A,p.Arg20Glu Homozygous mutation in JAGN1 
gene
P29 Yes WES SCN JAGN1 c.40G > A, p.Gly14Ser Homozygous mutation in JAGN1 
gene
P30 (E) Yes SNP mapping array MST1 def STK4 c.G750A, p.W250X Homozygous stop codon mutation in 
exon 7 of the gene STK4
P31 (E) Yes SNP mapping array MST1 def STK4 c.G750A, p.W250X Homozygous stop codon mutation in 
exon 7 of the gene
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family occurred in 48.9% of patients and was significantly 
higher in patients with CID7and innate immunity defects. 
Forty-three patients belonged to 16 kind reds, and gene 
mutations responsible for the PIDs were determined in 
21 individuals from 8 families. 100 and 75 patients were 
from families with low socioeconomic status, and no 
significant difference was seen in socioeconomic status 
between different groups of PID (Table 1).
Discussion
In the last decade, much effort has been devoted to estab-
lish biobanks for different research purposes. It has been 
a long-standing need to create a biobank for PID patients 
in Iran. Construction of such a biobank as a resource 
center of data and genome contents facilitates identifica-
tion of genetic defects underlying different types of PID, 
in spite of the generation of descriptive statistics. We cre-
ated a PIDB in order to stop the ad-hoc research studies, 
which may not have standard quality of sampling, pro-
cessing and storage.
In our population, 30 different PIDs were diagnosed 
and categorized into 8 main groups. This is a prelimi-
nary report of our PID biobank and database. Our study 
showed that antibody deficiency is the most common 
group of PIDs in Iran, which is consistent with other 
studies [29, 33–37]. The proportion of patients with 
antibody deficiency in total is almost similar to previ-
ous reports from Iran but lower than the last report from 
ESID (26 vs. 57%) [4, 37]. Congenital defect of phagocyte 
number and/or function is the second most predomi-
nant PID in our study, similar to studies from France, 
Malaysia, Korea, USIDNET8, Iran and Iceland [4, 36–39], 
and is in contrast with studies from other registries that 
reported combined immunodeficiency with associated/
syndromic feature as the second common one [33, 35, 
39, 40]. Phagocyte defect involved 23.9% of our patients 
and 42% of PIDs in Oman [41]. However, much lower 
frequency has been observed in ESID, UK, Turkey and 
Spain [35, 39, 42]. Combined immunodeficiency with 
associated/syndromic feature was the third prevalent 
PID, which accounts for 10% of patients in accordance 
with studies from France, Malaysia and UK. This group of 
PID was formerly known as well-defined syndromes, but 
it has been changed into combined immunodeficiency 
with associated/syndromic feature in the updated IUIS. 
Innate immunity defects and auto inflammatory diseases 
are followed by combined immunodeficiency and disease 
of immune dysregulation. Complement deficiency was 
the least prevalent subcategory in our study and also in 
the other surveys [39, 43]. CVID1 was the most frequent 
disorder in most studies [34, 39], which is in contrast 
with the last update of IPIDR that indicated SCID9 as the 
most common disorder in Iran [4].
It was not an unexpected finding that PID in males is 
more frequent than females (1.7:1), but we found a sig-
nificant difference in sex distribution in CID7, combined 
immunodeficiency with associated/syndromic feature, 
antibody deficiency and auto inflammatory disorders 
compared to other PID groups. The fact that males 
are more affected by PID is partially related to known 
X-linked disorders. Our registry included only 10 BTK10 




Method Disease Gene affected Mutation Comment
P32 (E) Yes SNP mapping array MST1 def STK4 c.G750A, p.W250X Homozygous stop codon mutation in 
exon 7 of the gene STK4
P33 No CVID panel Ab def (CD40L 
def )
TNFSF5 c.521A > G Homozygous mutation in TNFSF5 
gene
P34 (F) Yes NGS CGD CYBA c.388C > T; p.G130X Homozygous non-sense mutation 
in CYBA-encoding p22-phox:CAG 
codon change for Gln-130 → TAG 
stop codon
P 35 (F) Yes NGS CGD CYBA c.388C > T; p.G130X Homozygous non-sense mutation 
in CYBA-encoding p22-phox:CAG 
codon change for Gln-130 → TAG 
stop codon
P 36 (H) Yes WES CGD CYBB C730delT; 
p.Cys244ValfsX10
One base-pair deletion in CYBB, the 
X-ch linked gene encoding gp91-
phox
P 37 (H) Yes WES CGD CYBB C730delT; 
p.Cys244ValfsX10
One base-pair deletion in CYBB, the 
X-ch linked gene encoding gp91-
phox
* UI Under Investigation
Patients with the same letter in parentheses after their IDs are from one family
Page 9 of 11Sheikhbahaei et al. Allergy Asthma Clin Immunol  (2016) 12:62 
1 IPEX12 patients. An important finding is that, besides 
these known X-linked diseases, there is still a signifi-
cant difference in gender distribution in the mentioned 
groups. This finding may suggest the presence of undis-
covered X-linked patterns of inheritance in PID groups 
among our population. Few studies evaluated consan-
guinity in PID families. Our study is the first study to 
analyze consanguinity among different groups of PIDs, 
but no significant difference was observed. Recent stud-
ies and other registries from Islamic countries and also 
from Germany showed a higher rate of consanguine-
ous marriage in parents of PID patients compared to the 
rate reported from the UK and Turkey [35, 42]. In our 
PID population, consanguinity was mostly observed in 
patients with CID5 and CID with associated/syndromic 
feature. Our study evaluated the history of any known/
suspicious case of PID in family members of the patients, 
which was more frequent than in another report from 
Iran (48.9 vs. 28.9%) [4]. It is probably due to the con-
sideration of positive family history of PID in relatives of 
patients who did not yet have a definite genetic diagnosis.
Diagnostic delay in our study (5  years and 6  months) 
was much higher than that of other studies. This may 
be due to ignorance of symptoms and mismanagements 
of patients by inept physicians. The clinical evidence for 
this fact is that 22 patients suffer from bronchiectasis 
(11.7%). The delay from onset of symptoms to diagnosis 
was shorter in CID7 with syndromic/associated feature, 
because these patients have significant presentations, 
distinctive features in childhood or intrauterine defects 
including coarse faces, microcephaly, mental retarda-
tion, dwarfism, and IUGR, among others which cannot be 
neglected. Our registry also reports 7 deaths due to pri-
mary immunodeficiency disease that can be partly related 
to delayed or undiagnosed type of disease. As patients 
with PID are struggling with various recurrent infections, 
lifelong, and no definite treatment is known except bone 
marrow transplantation, in some cases, they just receive 
therapies in order to control signs and symptoms. Con-
sequently, these patients visit their clinical immunolo-
gists for follow up and renew their drugs frequently. Our 
last update revealed that 61 patients were not followed 
in the previous year, and we are unaware of their disease 
status. Mortality rate in our study (5.5%) is much lower 
when compared to the other report from Iran (18.7%) [4]. 
We established that most of the deceased patients suf-
fered from SCID9; however, our study included few cases 
of SCID9 and other severe PID cases leading to death. 
We also observed that most of the affected patients are 
from low socioeconomic status. This might be due to a 
lower level of education and not being aware of the risks 
associated with consanguineous marriage. Other stud-
ies indicated that lack of accurate clinical PID diagnostic 
criteria, unawareness of general practitioners and lack 
of referring to physicians in cases with mild presenta-
tions cause PIDs not to be discovered properly. Societies 
with advanced social awareness report statistics closer to 
the actual quantities. Therefore, long-term projects for 
improving social knowledge about primary immunodefi-
ciency diseases, their clinical presentations, consanguine-
ous marriage and its genetic effect on occurrence of PIDs 
are planned. We began our cooperation with the Stand-
ing Committee of Public Health in the International Fed-
eration of Medical Students Association. This standing 
committee is responsible for raising awareness regarding 
global public health issues. As a rule, the earlier the diag-
nosis is made, the sooner the treatment can commence 
and the lower morbidity and mortality can be expected.
Conclusion
Although a national registry has been established in Iran 
(IPIDR) [4], this is the first comprehensive biobank for 
PID patients in our country, which offers cross-country 
collaborations with the goal of identifying genetic diag-
nosis of these patients. Genome sequencing and definite 
diagnosis may help patients to receive effective treat-
ments and enjoy higher survival. Our study was designed 
to provide the PID Biobank (PIDB) in order to have a 
high quality DNA reservoir of these patients, share-
able for international diagnostic and therapeutic col-
laborations. We are keen to link with other international 
research centers in order to share data and samples. High 
prevalence of consanguinity makes PIDB samples valu-
able for collaborative projects. This article emphasizes on 
raising the awareness of society and general practitioners 
in order to achieve timely diagnosis of these patients and 
prevent current mismanagements.
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